Alchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK

in Portfolio News

Author: Tony Quested

Publication: Business Weekly

Illumina unveils the first global genomics accelerator cohort and Alchemab Therapeutics, an SV7 Impact Medicine Fund portfolio company, is among the three companies that comprise this funding cycle of Illumina Accelerator Cambridge UK.


View the article